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Abstract
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States

Cirrhotic patients with recurrent variceal bleeds who
have failed prior medical and endoscopic therapies and
are not transjugular intrahepatic portosystemic shunt
candidates face a grim prognosis with limited options.
We propose that mesocaval shunting be offered to this
group of patients as it has the potential to decrease
portal pressures and thus decrease the risk of recurrent
variceal bleeding. Mesocaval shunts are stent grafts
placed by interventional radiologists between the me
senteric system, most often the superior mesenteric
vein, and the inferior vena cava. This allows flow to
bypass the congested hepatic system, reducing portal
pressures. This technique avoids the general anesthesia
and morbidity associated with surgical shunt placement
and has been successful in several case reports. In this
paper we review the technique, candidate selection,
potential pitfalls and benefits of mesocaval shunt place
ment.
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Core tip: Cirrhotic patients who have recurrent variceal
hemorrhage despite medical and endoscopic therapy
have limited options if they are not transjugular intrahe
patic portosystemic shunting candidates. One promising
new method to decrease portal pressures while avoiding
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to her banding procedures that required inpatient
admission. Her PVT prohibited TIPS placement and she
consented to undergo endovascular mesocaval shunt
placement.
In our patient, and, in general, first, a needle is dir
ected, in our case transabdominally, through the SMV,
or, in this instance, a portal vein remnant, at a target
placed via internal jugular (IJ) access (Figure 2A). Then,
a wire is threaded from this needle through the IVC and
out the IJ access so that, when the needle is removed,
the distal tip of the the wire is in the splenic vein and
its proximal end functions as a guidewire exiting the IJ
access (Figure 2B). Finally, a stent graft, in our case a
covered VIATORR stent, is passed over the guidewire
via IJ access using Seldinger technique and placement
is confirmed with fluoroscopic guidance (Figure 2C).
[6]
In the initial case report , contrast-enhanced com
puted tomography (CT) was first performed to define
cross-sectional anatomy. The patient underwent bowel
preparation pre-procedurally and was given prophylactic
antibiotics as a transcolonic approach was anticipated.
Using CT and fluoroscopic guidance, a needle was inserted
through and through the transverse colon and SMV into
the IVC to a retrieval basket. The retrieval basket had
been placed in the IVC via the right internal jugular vein.
A guide wire was then passed from the abdominal access
through the SMV to IVC and jugular access. A stent was
placed under angiographic guidance from the internal
jugular access across the IVC to SMV and the wire was
removed.
[9]
Another case report, by Moriarty et al , used similar
methodology but opted for a transgastric rather than
transcolonic approach to reduce the risk of infection.
[9]
Interestingly, the case reported by Moriarty et al re
quired a cardiac transseptal needle to puncture the IVC
as attempts made with a Rosch-Uchida TIPS needle
were unsuccessful. The final published percutaneous
approach to date was remarkable for the ability to avoid
[8]
luminal puncture; Bercu et al were able to approach
transabdominally without perforating the bowel and relied
on fluoroscopic rather than CT-guidance for visualization
of the patient’s anatomy during the procedure.
[7]
Hong et al reported an interesting series of three
cases in which they were able to place mesocaval shunts
but avoid a transabdominal approach. Using techni
ques similar to direct intra-hepatic portosystemic shunt
(DIPS) placement, they describe a series of cases in
which they relied on intravascular ultrasound to avoid
transabdominal puncture to access the SMV. The stent
itself is extra-hepatic (and thus distinct from DIPS) and
possible in patients who are not candidates for TIPS or
DIPS given portal vein thrombi. In short, sheaths were
placed both femorally and in the internal jugular vein. A
guide wire was used to couple the jugular and femoral
sheaths. Following guide wire placement, a longitudinal
side-firing intravascular ultrasound (IVUS), akin to those
used in placement of DIPS, was introduced through the
femoral sheath so that the SMV could be cannulated
using a needle introduced at the jugular access. In this

surgical shunt placement is mesocaval shunt placement
with fluoroscopic guidance. In this paper we review the
technique, candidate selection, potential pitfalls and
benefits of mesocaval shunt placement.
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INTRODUCTION
Patients with cirrhosis and recurrent variceal bleeding
face a high mortality, 20% in the first year vs 5.4% for
[1]
compensated patients . Current standard of care for
variceal bleeding includes three primary modalities:
Medical therapy with beta blockade, endoscopic the
rapy with ligation of varices and shunt therapy with
transjugular intrahepatic portosystemic shunting (TIPS).
Each of these have been shown to improve rebleeding
[2-4]
rates and mortality .
For an unfortunate cohort of patients with varices who
fail medical and endoscopic therapy and are not TIPS
candidates, there are limited options in the face of a grim
prognosis. Historically, these patients have been offered
surgical shunt approaches, however, mortality of surgical
shunt placements is high - 20%-50% if emergent - and
[5]
many patients may not be suitable surgical candidates .
[6]
First described in 1996 by Nyman et al , mesocaval
shunting may provide an alternate route to alleviate
portal hypertension in these challenging patients. This
paper will review the technique, candidate selection,
potential pitfalls and benefits of mesocaval shunting.
While there are not enough data to comment on a mor
tality benefit, we believe that mesocaval shunting is a
feasible procedure for the prevention of variceal bleeding.
It will likely be most useful for patients whose anatomy
prohibits TIPS to provide a bridge to transplant.

TECHNIQUE
Mesocaval shunting involves the creation of a shunt
from the mesenteric vasculature, typically the superior
mesenteric vein (SMV), into the inferior vena cava
(IVC). Similar to TIPS, this provides relief of portal pre
ssures by allowing blood to bypass the congested
hepatic vasculature. Shunt placement is performed by
interventional radiologists. There have been both femoral
[6-9]
and transabdominal approaches reported (Table 1) .
Fluoroscopy from a recent case of refractory variceal
bleeding in a patient with a portal vein thrombus (PVT)
from our institution will be used to graphically illustrate
the basic technique (Figure 1). Our patient had cirrhosis
and prior medical and endoscopic attempts to control her
varices were limited by significant chest pain attributed

WJH|www.wjgnet.com

791

July 8, 2016|Volume 8|Issue 19|

Davis J et al . Mesocaval shunting for esophageal varices
Table 1 Summary of published mesocaval shunt placements
Ref.

Case history

Nyman et al[6] 1996

Details and outcomes

37-year-old male with history of recurrent massive variceal bleeds
attributed to congenital PVT and failed prior surgical shunt attempt

Moriarty et al[9] 2012

57-year-old male with history of metastatic CRC and extrahepatic PVT
who failed prior TIPs and was thought not to be surgical candidate

Bercu et al[8] 2015

58-year-old female with history of HCV cirrhosis, PVT with recurrent
ascites who failed prior TIPs attempt and was a poor surgical candidate

Hong et al[7] 2012

16-year-old female with history of chronic PVT and hematemesis who
was felt to have high surgical risk

Hong et al[7] 2012

60-year-old female with history of HBV, HCV, HCC with thrombus
obliterating PV

Hong et al[7] 2012

53-year-old male with history of pancreatic teratoma treated with
Whipple with clot at SMV and splenic veins

Visualization
Approach
Duration of follow-up
Thrombosis
Recurrent bleeding
Hepatic encephalopathy
Visualization
Approach
Duration of follow-up
Thrombosis
Recurrent bleeding
Hepatic encephalopathy
Visualization
Approach
Duration of follow-up
Thrombosis
Recurrent bleeding
Hepatic encephalopathy
Visualization
Approach
Duration of follow-up
Thrombosis
Recurrent bleeding
Hepatic encephalopathy
Visualization
Approach
Duration of follow-up
Thrombosis
Recurrent bleeding
Hepatic encephalopathy
Visualization
Approach
Duration of follow-up
Thrombosis
Recurrent bleeding
Hepatic encephalopathy

CT angiography
Transcolonic
5, 12 and 14 mo
Yes1
No
NR
CT and fluoroscopy
Transgastric
3 mo
Yes2
Yes2
NR
Fluoroscopy
Transabdominal
3 and 6 mo
No
No
Yes3
Fluoroscopy and IVUS
Endovascular
1 mo
No
No
NR
Fluoroscopy and IVUS
Endovascular
2 and 10 mo
No
No
NR
Fluoroscopy and IVUS
Endovascular
1 and 3 mo
No
No
NR

1

The shunt was found to be thrombosed on POD #1 so the patient underwent ballooning of his stent and directed thrombolysis and was started on a
therapeutic heparin. His hematocrit began to fall on the heparin but stabilized when the anticoagulation was held; 2The shunt was found to be thrombosed on
POD #2 and on POD #3 the patient had a recurrent upper gastrointestinal hemorrhage. A new shunt was placed and the patient had no further bleeding; 3The
patient had no encephalopathy at a 3-mo follow-up visit but was noted by an outside hospital to have encephalopathy 6 mo after shunt placement when the
patient was hospitalized for concern for partial small bowel obstruction. The patient’s home lactulose and rifaximin had been held; when these medicines were
resumed her encephalopathy resolved. NR: Not reported; PVT: Portal vein thrombus; CRC: Colorectal cancer; TIPs: Transjugular intrahepatic portosystemic
shunting; HCV: Hepatitis C virus; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; SMV: Superior mesenteric vein; PV: Portal vein; CT: Computed
tomography.

way, they were able to avoid a percutaneous transab
dominal approach altogether. It should be noted that the
third patient included in this series was not a cirrhotic
patient but rather had portal and SMV clots due to a
pancreatic tumor; we chose to include this patient in our
review to demonstrate the feasibility of the procedure but
appreciate that his underlying pathophysiology may be
different from the others presented.

didates, particularly the group awaiting transplant, as
there are not yet mortality data for mesocaval shunting
and the mortality benefit of other portosystemic shunts,
[10]
including TIPs, has been questioned .
As in our illustrative case, PVT, for example, are known
to make TIPS more difficult and result in lower success
[11]
rates, ranging from 40%-75% . In some cases, when
PVT is chronic, TIPS is not only difficult but actually tech
nically impossible as in order to re-establish flow, there
must be functional vessels surrounding the planned
recanalized clot segment. This intact vasculature is
often absent in those with chronic PVT as intrahepatic
vessels may have atrophied while extrahepatic vessels
[6]
form collaterals at high risk of bleeding . Given the
relatively high prevalence of PVT in cirrhotics, up to 5%
to 16% of patients at the time of liver transplantation,
mesocaval shunting has the potential to offer a therapy

SELECTION OF CANDIDATES
Candidates likely to benefit from mesocaval shunt
ing include those with recurrent variceal bleeds who
have failed prior medical and endoscopic therapies.
Traditionally, TIPS has been employed in these patients
to alleviate portal pressures. We propose that mesocaval
shunting be offered to patients who are not TIPS can
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bowel hematomas - which was successfully treated
conservatively with intravenous fluid, transfusion support
[6]
and discontinuation of anticoagulation . If the cannulated
vesels require predilation prior to shunt placement, this
[7]
risk of bleeding is likely increased . Finally, while they
did not experience intrabdominal hemorrhage despite
[9]
use of an uncovered stent, Moriarty et al note that use
of an uncovered stent certainly increases risk of bleeding
and recommend using covered stents and/or balloons to
minimize this risk. In addition to procedural technique,
we anticipate that, similar to other invasive procedures
in cirrhotic patients, platelet counts influence the risk of
hemorrhage. The cases reviewed here unfortunately do
not provide patient platelet counts or other measures of
clotting function.
In addition to the potential for vessel perforation,
depending on each individual patient’s anatomy, there
are risks of perforation of different structures. If an intes
tinal perforation is created, risk of sepsis, hemorrhage
[8]
and/or abscess formation will certainly be increased .
In two reported cases, the transabdominal approach
[6,9]
necessitated intestinal puncture . In one case the
track was transcolonic while the other approach was
transgastric. Bowel preparation and antibiotic prophylaxis
were administered in the transcolonic case and neither
case resulted in sepsis. Although there were no reported
infectious complications in the cases we reviewed, this
risk should be underscored as it is likely not negligible in
cirrhotic patients with impaired immunity. In addition to
the risk of intestinal perforation, other nearby viscera are
at risk of puncture as well. If the pancreas is punctured,
[8]
both hemorrhage and pancreatitis are potential risks .
One published case to date notes pancreatic bisection
and reports that serum amylase levels were within the
[7]
normal range for at least five days post-operatively .
In the six cases reviewed, two cases reported sub
sequent shunt occlusion and need for further revision,
a rate of 33% in our, appreciably, small series. Shunt
thrombosis is an important outcome as it presumably
puts the patient at risk for further portal hypertension,
variceal formation and variceal bleeding. In the first of the
two cases complicated by occlusion, lack of flow through
the shunt was noted on both Doppler and CT on POD
[6]
#2 . The patient underwent repeat angiography and
had ballooning and directed thrombolysis of his stent with
subsequent patency on 5 mo follow-up angiogram. The
stent was again noted to be occluded on 12 mo followup angiography but he had no further gastrointestinal
bleeding and no attempt to revise the shunt further was
made. In the second case complicated by shunt occlusion,
lack of flow through the shunt was noted on POD #2 on
[9]
CT . This was attributed to the severe angle of the initial
shunt placement and its proximity to the wall of the IVC.
This patient experienced upper gastrointestinal bleeding
on POD #3 and underwent repeat angiography with
stent replacement and had a patent stent and no further
bleeding at 3 mo follow-up.
Finally, as with any form of portosystemic shunting,
we anticipate that these patients will have higher rates

Figure 1 Grade Ⅲ varices in distal esophagus on pre-procedure esopha
gogastroduodenoscopy.

to a large group of patients who were previously thought
to be without options, particularly in those patients whose
[12]
PVT prohibits them from receiving a liver transplant .
Prior to endovascular placement of mesocaval shunts,
the other option for patients in this scenario was sur
gical shunt placement. Historically, surgically placed
[5]
portosystemic shunts have had high mortality . While
experienced centers are reporting improved opera
[13,14]
tive mortality
, the ability to replicate these lower
mortality rates at smaller, less experienced centers
remains to be seen. Furthermore, several of the patients
in published percutaneous mesocaval shunt cases to
date were thought to be poor surgical shunt candidates
due to a history of prior abdominal surgeries and/or
[6,8,9]
anatomy of their PVT
.
If a patient is felt to be appropriate for consideration
of mesocaval shunt placement, assessment of crosssectional anatomy should be undertaken with computed
tomography or magnetic resonance imaging of the
abdomen to assist in procedural planning. For successful
shunt placement, the IVC and SMV should be aligned
and proximal in an anatomic window without any signi
ficant vasculature or viscera interposed between the two
[8]
vessels . The IVC and SMV (or a large collateral) must
be patent for shunt placement.

POTENTIAL PITFALLS
There are a few potential pitfalls we consider with place
ment of a mesocaval shunt. First, similar to the surgical
expertise required for safe surgical shunt placement,
institutional interventional radiologic expertise will be
required to safely recommend this procedure and this
may not be available at all centers. This procedure,
unlike TIPS, has not been reported to be performed in
the setting of active variceal bleeding and thus there are
no data to support its safety in that setting.
The most serious risk is that of procedure-related
hemorrhage due to puncture of proximal vasculature.
[7]
As noted by Hong et al both the SMV and infrahepatic
IVC lack any surrounding solid organs that could provide
tamponade during shunt placement, creating a risk
of major hemorrhage. Of the published cases to date,
one noted intraabdominal hemorrhage-multiple small
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A

C

B

RT

Figure 2 Intra-procedure steep oblique fluoroscopy of upper abdomen during mesocaval shunt placement. First, a needle is inserted percutaneously (black
arrowhead) and directed through the portal vein remnant at a target snare placed in the inferior vena cava (white arrowhead) via internal jugular (IJ) access sheath
(red arrowhead) (A). The wire is then threaded from its original percutaneous entry via the needle through the IJ sheath (red arrowhead) so that it extends from the
IJ and is seen coiling in the splenic vein (black arrowhead) (B). The unexpanded stent graft (white arrowhead) is passed over the wire using Seldinger technique with
fluoroscopic guidance (B). Coils are placed in varices (blue arrowhead) (B). Shuntogram with contrast 22 mo post-procedure shows functioning mesocaval shunt (white
arrowhead) with tip in the splenic vein (black arrowhead) and absent varices (C). Previous coils in the varices are still visible (red arrowhead).

three months follow-up respectively. One shunt ultimately
lacked patency at 12 mo follow-up but the patient had
no further bleeding up to 14 mo follow-up. In summary,
all reported cases have follow-up ranging from 1 to 14
mo in which, with the exception of the post-operative
day 2 bleed noted above, there were no further variceal
bleeding episodes. These are promising results in light of
the known 60% 1-year risk of rebleeding and 33% 1-year
mortality in patients who survive an episode of variceal
[17]
hemorrhage .
In addition to offering a rescue therapy for a group
of patients with minimal options, mesocaval shunting
has an advantage compared to local variceal therapy, it
will result in lower portal pressures and thus will reduce
recurrent ascites as well reducing the risk of variceal
bleeding. As noted by Garcia-Tsao and Bosch in a recent
review, judgment of treatment success of varices
should include mindfulness about the impact of variceal
treatment on other complications of portal hypertensionascites, jaundice, encephalopathy - rather than artificially
isolating the treatment’s impact on variceal bleeding
[17]
alone . Finally, given that the presence of portal vein
thrombosis is no longer thought to be an absolute con
[18]
traindication to transplant , for those patients that
are transplant eligible, placement of a mesocaval shunt
may enable survival to the operating room table for
transplant, a pressing concern given that our most recent
national statistics are dire. In 2014, 1821 patients died
while awaiting transplant and an additional 1290 were
removed from the waiting list as they were felt to be “too
[19]
sick” for transplant .

of hepatic encephalopathy (HE) than patients without
portosystemic shunting. Given the limited numbers of
patients who have undergone percutaneous or endo
vascular mesocaval shunt placement, there are no
data to evaluate rates of HE with these shunts vs TIPS
or surgical shunt creation but presumably the rate is
[15,16]
similar, around 30%
. In the cases reviewed above,
only one case reported on the presence or absence of
encephalopathy. In that case, the patient was noted to
have no encephalopathy during index hospitalization or
at 3 mo follow-up but was noted to be encephalopathic
6 mo post-operatively when her lactulose and rifaximin
were held at an outside hospital for partial small bowel
[8]
obstruction . Her encephalopathy reportedly resolved
with resumption of these medications.

BENEFITS
As above, mesocaval shunting offers a treatment for
bleeding varices for patients who otherwise face a high
mortality with virtually no options. It can be offered to
patients with PVT who cannot undergo TIPS and may
be best utilized as a bridge to transplant. Furthermore,
if an IVUS is utilized, vessels are directly visualized,
[7]
avoiding the blind puncture method used in TIPS . As
with other similar endovascular procedures, we anticipate
a lower mortality with this less invasive approach vs
surgical shunt placement. Regardless, the majority of
the published patients to date were not felt to be surgical
[6,7,9]
candidates
.
In the six adult cases published to date, two stents
thrombosed within two days post-operatively while the
[6,9]
remaining four remained patent . Of the two patients
with shunt thrombosis, one had a recurrent upper gas
trointestinal bleed. In this case, it was postulated that
the severe angle of the initial stent placement may have
[9]
contributed to turbulence and subsequent thrombosis .
In both cases, subsequent shunt revision was performed
and the revised shunts remained open during five and
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As reviewed above, endovascular mesocaval shunting is
a feasible procedure that offers a promising intervention
to a patient population with few options and one-year
[1]
mortality as high as 20% . TIPS has been shown to be
an effective intervention to prevent recurrent variceal
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[2]

bleeding and mesocaval shunting provides similar
physiologic relief of portal pressure in patients who are
not TIPS candidates. Like TIPS, mesocaval shunting
avoids major surgery and may require less anesthesia
than a surgical shunt approach. Furthermore, it can be
offered to patients who are not surgical candidates.
Mesocaval shunting alleviates portal hypertension, a key
component of reducing the rate of variceal bleeding,
and one that will potentially reduce recurrent ascites
as well. The patient who stands to gain the most from
this procedure has recurrent variceal bleeds, has failed
endoscopic and medical therapies, cannot undergo
TIPS due to anatomy and needs a bridge to transplant
to minimize the chance of further decompensating
while awaiting an organ. In order to have successful
shunt placement, these patients must have alignment
between IVC and SMV or SMV collaterals. Potential
procedural complications include perforation of nearby
vessels or viscera which could result in hemorrhage,
sepsis, pancreatitis or abscess formation as well as
stent thrombosis. Placement of a portosystemic shunt
will also increase the risk of hepatic encephalopathy
although there is little data to compare mesocaval shunts
to surgical shunts or TIPS. To date, several approaches
and imaging techniques have been utilized by reporting
groups, notably including one approach that avoids tran
[7]
sabdominal puncture . In the cases reported, all have
prevented rebleeding for the post-procedural monitoring
[6,8,9]
period after initial shunt or initial shunt revision
.
Further research should be performed to better assess
outcomes - variceal bleeding, hepatic encephalopathy
rates and mortality - in these patients compared to
standard-of-care controls so that the benefits of this
promising technique may be maximized.
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